AC Immune SA (STU:IMR)
€ 3.705 -0.3 (-7.49%) Market Cap: 376.55 Mil Enterprise Value: 270.11 Mil PE Ratio: 0 PB Ratio: 2.48 GF Score: 58/100

AC Immune SA at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript

Apr 28, 2022 / 03:30PM GMT
Release Date Price: €3.2 (-5.49%)
Mayank Mamtani
B. Riley Securities, Inc. - Analyst

Good morning. Thank you all for joining us for our next fireside chat with AC Immune CEO, Professor Andrea Pfeifer. Thank you, Andrea, for joining us. I know you have a lot going on, and you are in a completely different time zone, so all the more appreciate it.

And maybe we can get started with a high-level overview of your pipeline focused on neurodegenerative diseases coming across therapeutics and diagnostics. And then obviously, we have a ton to talk about as we deep dive into your programs.

Andrea Pfeifer
AC Immune SA - Co-Founder, CEO & Director

Yes. So I think, starting off, it would be very important to basically talk about the upcoming milestones. So as you know, we have pipeline targeting Tau, Abeta, alpha-synuclein in late-stage disease. And we have a preclinical pipeline targeting inflammasome, TDP-43.

So on the late-stage pipeline, we are really looking forward to the readout of the API study, evaluating consumer -- the anti-Abeta antibody in a genetic population in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot